NYXH Rasio cepet Nyxoah S.A.

The price action of Nyxoah S.A. (NYXH), which operates in the medtech sector, is currently at 2.21. Current performance is driven by the outsourcing of module assembly and the delegation of services in Western countries. Meanwhile, aggressive marketing of apnea treatments is causing a liquidity shortage, as expenses are outpacing profits. Business stability is further constrained by raw material logistics challenges and stringent foreign certification requirements.

Establishing a long-term position in Nyxoah S.A. (NYXH) requires strict solvency control to mitigate regulatory risks. The specifics of neurostimulation implementation and reliance on insurance reimbursements leave the company vulnerable to cash flow gaps. This critical test ratio measures the ability to settle short-term liabilities using only cash and accounts receivable, ignoring illiquid inventories. The stability of this metric confirms the business's resilience against competition from CPAP therapy.